Interestingly, in breast cancer cells, an opposite effect has been observed, where an increase in SVCT2 levels would favor AA-mediated toxicity, while the use of siRNA against SVCT2 confers resistance to AA treatment [75], suggesting that the effects of SVCT2 are tissue-specific. This evidence concerns the gene SLC23A2 and breast cancer.